Selexipag not checked

Actelion · JNJ-67896049 · ACT-293987

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
3 active
19 in total · 3 in the EU

What this is

How it works
Prostacyclin Receptor Agonist FDA class
How it’s given
“Adult Participant will receive oral dose of selexipag tablet twice daily at the dose strength corresponding to their maintenance dose at the end of their parent study. Available strengths: 200, 400, 600, 800, 1000, 1200, 1400 and 1600 micrograms (µg). Children with body weight category of \>=50 kg will use the tablets at the required dose strength as described for adults. Children with a body…”In the company’s words, NCT05179876 on ClinicalTrials.gov
Tested for
Hypertension, Pulmonary (2 trials), Pulmonary Arterial Hypertension
Main trialPhase 3
“The purpose of this study is to evaluate whether the addition of selexipag to standard of care treatment delays disease progression in children with Pulmonary Arterial Hypertension (PAH) in comparison to placebo.”In the company’s words, NCT04175600 on ClinicalTrials.gov
Other names
JNJ-67896049 · ACT-293987 · Uptravi

Other drugs for Hypertension, Pulmonary

All 29 drugs for Hypertension, Pulmonary

Copies tested against it1

Other companies’ versions, mostly cheaper copies for when the patent ends

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials19

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 11 Oct 2024 A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension
Phase 3Recruiting 31 Jan 2027 A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option
Phase 2Active, not recruiting 28 Mar 2022 A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension
Phase 4Completed 10 Feb 2020 Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.
Phase 4Terminated 28 Jul 2023 A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging
Phase 3Completed 1 Apr 2014 Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
Phase 3Completed 29 May 2018 Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension
Phase 3Completed 29 Aug 2019 The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
Phase 3Completed 26 Aug 2021 ACT-293987 in Pulmonary Arterial Hypertension
Phase 3Terminated 7 Jun 2022 A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment
Phase 3Completed 10 Nov 2023 A Study of Selexipag in Participants Who Participated in a Previous Selexipag Study
Phase 2Completed 30 Apr 2015 Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis
Phase 2Terminated 19 Apr 2023 A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag
Phase 1Completed Dec 2012 Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μg
Phase 1Completed Apr 2015 Absolute Bioavailability of a Single Oral Dose of Selexipag in Healthy Subjects
Phase 1Completed Jun 2016 Comparison of Two Dose Strengths of Selexipag in Healthy Adults
Phase 1Completed Jul 2016 A Clinical Study to Investigate the Effect of Gemfibrozil or Rifampicin on Blood Concentrations of Selexipag in Healthy Subjects
Phase 1Completed 10 May 2018 A Clinical Study to Assess the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite in Healthy Male Subjects
Phase 1Completed 14 Aug 2020 A Study of Selexipag in Healthy Male Participant
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Selexipag

Following is part of Solo: you see every change to Selexipag the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in